By Sheeba M. | April 26, 2026
The Cannabis Cash Flow Story Nobody’s Talking About: Why EBITDA Is the New EPS
If you’ve been buying cannabis stocks based on “P/E ratios,” stop. You’re doing it wrong. Most cannabis operators post negative net income thanks to Section 280E of the tax code, which prohibits cannabis businesses from deducting ordinary business expenses. It’s a tax trap that makes GAAP earnings useless as a valuation metric.
Smart capital is now focused on EBITDA and free cash flow—and the spreads between operators are massive. This is where the real alpha is hiding.
Section 280E: The Tax Trap Nobody Escapes
Here’s how the tax trap works: A cannabis MSO might post $1 billion in revenue. After cultivation, distribution, retail operations, and inventory costs, they have $200M in EBITDA. But Section 280E says they can’t deduct ordinary business expenses (R&D, marketing, office costs, etc.) from taxable income. Result: They pay federal tax on the full $1B revenue, not the $200M profit.
This crushes net income. Some operators show negative net income despite being profitable on a cash basis. Wall Street doesn’t like negative earnings, so MSO stocks trade at 5-8x EBITDA instead of 12-15x P/E like normal companies. It’s a valuation discount that creates opportunity for investors who understand the difference.
The EBITDA Spread Is Where Alpha Lives
CRLBF (Cresco Labs): 22% EBITDA margin
CURLF (Curaleaf): 18% EBITDA margin
TCNNF (Trulieve): 20% EBITDA margin
GTBIF (Green Thumb): 19% EBITDA margin
That 4-point spread between Cresco and Curaleaf doesn’t sound big until you do the math. On $400M+ in quarterly revenue, a 4-point margin swing = $16M in quarterly EBITDA. Over a year, that’s $64M—enough to fund M&A, return cash to shareholders, or fund debt paydown. The operator with superior margins can outgrow peers without raising capital.
Free Cash Flow: The Real Story
EBITDA is important, but free cash flow is the actual test. An operator can post 25% EBITDA but still burn cash if capital intensity is too high (building new cultivation, retail build-outs, etc.). The operators turning EBITDA into cash for shareholders are the ones that survive consolidation.
CRLBF generated positive free cash flow in Q1 2026 for the first time in two years. CURLF is still capex-heavy and burning cash. Wall Street doesn’t see it yet, but that’s a massive competitive advantage for Cresco. They can fund growth and shareholder returns. Curaleaf has to raise capital or cut growth.
Why This Matters for Your Portfolio
The cannabis sector is bifurcating: Operators with 20%+ EBITDA margins and positive free cash flow are becoming investment-grade quality. Operators with sub-18% margins and negative cash flow are struggling and may get acquired at discounts or face dilution from capital raises.
If you’re picking individual MSO names, the question isn’t “Is this company profitable?” (None of them are by GAAP). The question is: “Can they turn EBITDA into cash and fund growth without dilution?” Start with that filter, and your cannabis portfolio will outperform.
Sources
- IRS Section 280E Documentation — Tax code detail on cannabis expense deductions
- Cresco Labs Investor Relations — Q1 2026 EBITDA and cash flow data
- MG Magazine Cannabis Industry Report — Sector EBITDA benchmarks
Track cannabis stocks with the Weedstock Real-Time Tracker